Vimarsana
Biggest News Aggregation in the World

Kidney Int News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kidney Int. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kidney Int Today - Breaking & Trending Today

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Published: May 25, 2024

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Source: prnewswire.com
Related Topics:
Czech RepublicUnited StatesParag MahantiDavid SoergelPrnewswire NovartisMarianne SilkjMarlena AbdinoorJonathan GrahamDavid KavanaghSloan SimpsonFaculty Of Medical Sciences At Newcastle UniversityUniversity Of WashingtonG Steering Committee MemberMetabolism Development UnitEuropean Renal AssociationNovartis Pharmaceuticals CorporationExchange CommissionGlomerular Diseases Work GroupProfessor David KavanaghComplement TherapeuticsHonorary Consultant NephrologistMedical SciencesNewcastle UniversitySteering CommitteeGlobal Head
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - Vimarsana News

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

Published: May 25, 2024

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%...

Source: prnewswire.com
Related Topics:
United StatesJonathan GrahamMarlena AbdinoorSloan SimpsonLoreto MdaParag MahantiLambers HeerspinkBartonm EndothelinMichael MeoNovartis FabhaltaPrnewswire NovartisEuropean Renal AssociationFibrotic Transcriptional NetworksNovartis Pharmaceuticals CorporationExchange CommissionEndpoint AnalysisAtrasentan Shows Significant ReductionIga NephropathyEndothelin Receptor Typeb ExpressionGlomerular DiseasesReceptor ImmunoreactivityEndothelin AntagonistsChronic KidneyImproving Global OutcomesPractice Guideline
Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio - Vimarsana News

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

Published: May 25, 2024

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

Source: finanznachrichten.de
Related Topics:
United StatesSloan SimpsonNicole Zinsli SommLambers HeerspinkJonathan GrahamSatoshi SugimotoParag MahantiMarlena AbdinoorImke KappesIsabella ZinckNovartis FabhaltaMichael MeoLoreto MdaBartonm EndothelinExchange CommissionEuropean Renal AssociationFibrotic Transcriptional NetworksEndpoint AnalysisAtrasentan Shows Significant ReductionIga NephropathyEndothelin Receptor Typeb ExpressionGlomerular DiseasesReceptor ImmunoreactivityEndothelin AntagonistsChronic Kidney
Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Published: May 25, 2024

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Source: finanznachrichten.de
Related Topics:
United StatesCzech RepublicImke KappesMarlena AbdinoorDavid SoergelMichael MeoSloan SimpsonJonathan GrahamParag MahantiIsabella ZinckMarianne SilkjDavid KavanaghNicole Zinsli SommSatoshi SugimotoFaculty Of Medical Sciences At Newcastle UniversityGlomerular Diseases Work GroupMetabolism Development UnitExchange CommissionEuropean Renal AssociationG Steering Committee MemberUniversity Of WashingtonProfessor David KavanaghComplement TherapeuticsHonorary Consultant NephrologistMedical Sciences
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy - Vimarsana News

Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy

Published: February 16, 2024

PRINCETON, N.J. & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Feb 16, 2024--

Source: eagletribune.com
Related Topics:
United StatesBarrattj IgRobert MurphyJeffrey GilbertJohn KrausChristopher KieferBrian Jg PereiraOtsuka Pharmaceutical Co LtdCorporate CommunicationsVisterra IncOtsuka America IncOtsuka Pharmaceutical Development Commercialization IncGlomerular Diseases Work GroupOtsuka America Pharmaceutical IncDrug AdministrationOtsuka Pharmaceutical Company LtdOtsuka Holdings Co LtdPharmaceutical DevelopmentOtsuka PharmaceuticalBreakthrough TherapyNew England JournalBiological Licensing ApplicationProliferation Inducing LigandOtsuka Pharmaceutical DevelopmentOtsuka America Pharmaceutical